Clinical Trial Update: A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) Vaccine [Phase 3]

View source ↗

Summary

Clinical trial update for a Phase 3 study evaluating immunogenicity and safety of a nonavalent HPV vaccine.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Papillomavirus Infection

Drugs mentioned

• Nonavalent Human Papillomavirus Vaccine (null)

Snippet

Sponsor: Beijing Health Guard Biotechnology, Inc | Conditions: Human Papillomavirus Infection | Phase 3 | Status: UNKNOWN